Comprehensive literature review of protein C concentrate use in patients with severe congenital protein C deficiency.
Ontology highlight
ABSTRACT: Severe congenital protein C deficiency (SCPCD) is a rare disorder associated with life-threatening purpura fulminans and disseminated intravascular coagulation that typically present within hours after birth. Treatment options for patients with SCPCD include replacement therapy with a plasma-derived protein C concentrate. In this targeted literature review, we summarize information on the use of protein C concentrate as long-term prophylaxis (>1 week of treatment) for patients with SCPCD. In total, 18 publications were included in the review, of which 15 were case studies. Treatment with protein C concentrate (Ceprotin; Baxalta US Inc, a Takeda company; Takeda Manufacturing Austria AG) was reported in 11 publications, and treatment with protein C concentrate (Protexel; LFB Biomedicaments)
SUBMITTER: Siffel C
PROVIDER: S-EPMC11403366 | biostudies-literature | 2024 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA